Cargando…

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy

Mineralocorticoid receptor (MR) signaling which is closely associated with hypertension plays important roles in resistance to antiandrogen therapy in prostate cancer. However, its impact on the prognosis in androgen-deprivation therapy (ADT) has not been elucidated. Then, we investigated the impact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shiota, Masaki, Fujimoto, Naohiro, Imada, Kenjiro, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Tatsugami, Katsunori, Kajioka, Shunichi, Uchiumi, Takeshi, Eto, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6305359/ https://www.ncbi.nlm.nih.gov/pubmed/30619769 http://dx.doi.org/10.3389/fonc.2018.00635

Ejemplares similares

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2020)

Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
por: Akitake, Naoko, et al.
Publicado: (2018)

Equol inhibits prostate cancer growth through degradation of androgen receptor by S‐phase kinase‐associated protein 2
por: Itsumi, Momoe, et al.
Publicado: (2016)

Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
por: Hirata, Yu, et al.
Publicado: (2019)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy
por: Shiota, Masaki, et al.
Publicado: (2015)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Association of Missense Polymorphism in HSD3B1 With Outcomes Among Men With Prostate Cancer Treated With Androgen-Deprivation Therapy or Abiraterone
por: Shiota, Masaki, et al.
Publicado: (2019)

Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide
por: Kashiwagi, Eiji, et al.
Publicado: (2022)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

The Role of Nuclear Receptors in Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2019)

An oral first‐in‐class small molecule RSK inhibitor suppresses AR variants and tumor growth in prostate cancer
por: Ushijima, Miho, et al.
Publicado: (2022)

Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
por: Blas, Leandro, et al.
Publicado: (2023)

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
por: Chikamatsu, Sotaro, et al.
Publicado: (2022)

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade
por: Tanaka, Kentaro, et al.
Publicado: (2018)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Antiandrogenic Effects of a Polyphenol in Carex kobomugi through Inhibition of Androgen Synthetic Pathway and Downregulation of Androgen Receptor in Prostate Cancer Cell Lines
por: Kudo, Yudai, et al.
Publicado: (2022)

Genetic variations predicting progression with docetaxel and novel androgen‐receptor pathway inhibitors
por: Shiota, Masaki, et al.
Publicado: (2023)

Long‐term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old
por: Blas, Leandro, et al.
Publicado: (2021)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
por: Inokuchi, Junichi, et al.
Publicado: (2019)

Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer
por: Shiota, Masaki, et al.
Publicado: (2021)

Cyclophosphamide-Induced Tolerance in Allogeneic Transplantation: From Basic Studies to Clinical Application
por: Kato, Koji, et al.
Publicado: (2020)

Extracellular vesicles expressing CEACAM proteins in the urine of bladder cancer patients
por: Igami, Ko, et al.
Publicado: (2022)

Expression of androgen receptor in non-muscle-invasive bladder cancer predicts the preventive effect of androgen deprivation therapy on tumor recurrence
por: Izumi, Koji, et al.
Publicado: (2016)

Successful management of cryptococcosis of the bilateral adrenal glands and liver by unilateral adrenalectomy with antifungal agents: a case report
por: Matsuda, Yayoi, et al.
Publicado: (2011)

Editorial Comment to Resumption of anti‐programmed cell death 1 monotherapy for severe immune‐related adverse events experienced patient with renal cell carcinoma
por: Takeuchi, Ario, et al.
Publicado: (2020)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Activators and Inhibitors of Protein Kinase C (PKC): Their Applications in Clinical Trials
por: Kawano, Takahito, et al.
Publicado: (2021)

Protein Kinase C (PKC) Isozymes as Diagnostic and Prognostic Biomarkers and Therapeutic Targets for Cancer
por: Kawano, Takahito, et al.
Publicado: (2022)

Androgen deprivation therapy prevents bladder cancer recurrence
por: Izumi, Koji, et al.
Publicado: (2014)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Radiotherapy plus androgen deprivation therapy for prostate‐specific antigen persistence in lymph node–positive prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2022)

Doxycycline induces apoptosis via ER stress selectively to cells with a cancer stem cell-like properties: importance of stem cell plasticity
por: Matsumoto, Takashi, et al.
Publicado: (2017)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0tj9iljckbigekrvabdchmf3s6